Brokerages Set Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Target Price at $12.17

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) has received a consensus recommendation of “Moderate Buy” from the seven ratings firms that are covering the company, Marketbeat reports. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $12.17.

Several equities analysts have weighed in on IRWD shares. Leerink Partners assumed coverage on shares of Ironwood Pharmaceuticals in a report on Monday, September 9th. They set a “market perform” rating and a $5.00 price target on the stock. StockNews.com raised shares of Ironwood Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, July 16th. Wells Fargo & Company decreased their price target on Ironwood Pharmaceuticals from $14.00 to $12.00 and set an “overweight” rating on the stock in a report on Friday, August 9th. Leerink Partnrs raised Ironwood Pharmaceuticals to a “hold” rating in a research note on Monday, September 9th. Finally, Capital One Financial cut Ironwood Pharmaceuticals from an “overweight” rating to an “equal weight” rating and cut their target price for the stock from $12.00 to $4.00 in a research report on Thursday, August 8th.

Ironwood Pharmaceuticals Trading Down 2.6 %

IRWD opened at $4.08 on Friday. The firm’s 50 day simple moving average is $4.45 and its two-hundred day simple moving average is $5.91. The company has a market capitalization of $638.64 million, a PE ratio of -0.60 and a beta of 0.48. Ironwood Pharmaceuticals has a 1-year low of $3.79 and a 1-year high of $15.70.

Insider Transactions at Ironwood Pharmaceuticals

In related news, insider Minardo John sold 9,910 shares of the stock in a transaction that occurred on Monday, August 12th. The stock was sold at an average price of $4.27, for a total transaction of $42,315.70. Following the completion of the transaction, the insider now directly owns 284,661 shares of the company’s stock, valued at approximately $1,215,502.47. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 12.90% of the company’s stock.

Institutional Investors Weigh In On Ironwood Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the business. PNC Financial Services Group Inc. grew its stake in shares of Ironwood Pharmaceuticals by 152.2% in the 4th quarter. PNC Financial Services Group Inc. now owns 4,383 shares of the biotechnology company’s stock worth $50,000 after buying an additional 2,645 shares in the last quarter. CWM LLC increased its stake in Ironwood Pharmaceuticals by 55.1% during the second quarter. CWM LLC now owns 6,600 shares of the biotechnology company’s stock worth $43,000 after acquiring an additional 2,345 shares during the last quarter. SG Americas Securities LLC purchased a new stake in Ironwood Pharmaceuticals during the first quarter valued at approximately $91,000. GAMMA Investing LLC lifted its stake in shares of Ironwood Pharmaceuticals by 344.1% in the 2nd quarter. GAMMA Investing LLC now owns 10,526 shares of the biotechnology company’s stock valued at $69,000 after purchasing an additional 8,156 shares during the last quarter. Finally, EntryPoint Capital LLC boosted its holdings in shares of Ironwood Pharmaceuticals by 517.4% in the 1st quarter. EntryPoint Capital LLC now owns 10,589 shares of the biotechnology company’s stock worth $92,000 after purchasing an additional 8,874 shares during the period.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.